Failure of natalizumab to prevent relapses in neuromyelitis optica.
about
Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumabTh17 Cells Pathways in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Pathophysiological and Therapeutic ImplicationsTherapy of NMO spectrum disordersUltrahigh field MRI in clinical neuroimmunology: a potential contribution to improved diagnostics and personalised disease managementInternational consensus diagnostic criteria for neuromyelitis optica spectrum disordersCell-surface central nervous system autoantibodies: clinical relevance and emerging paradigmsImmunology of neuromyelitis optica: a T cell-B cell collaborationTreatment of neuromyelitis optica: state-of-the-art and emerging therapiesLongitudinally extensive optic neuritis as an MRI biomarker distinguishes neuromyelitis optica from multiple sclerosisEvaluation of a multiparametric immunofluorescence assay for standardization of neuromyelitis optica serologyMOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcomeCurrent concept of neuromyelitis optica (NMO) and NMO spectrum disorders.Optic neuritis in neuromyelitis optica.Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography.Clinical spectrum and treatment of neuromyelitis optica spectrum disorders: evolution and current status.Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.[Ultrahigh field MRI in context of neurological diseases].Neuromyelitis optica: clinical features, immunopathogenesis and treatment.Efficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorderSystemic Lupus Erythematosus (SLE) Complicated by Neuromyelitis Optica (NMO - Devic's Disease): Clinic-Pathological Report and Review of the Literature.Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS.Differential diagnosis of neuromyelitis optica spectrum disorders.The treatment of neuromyelitis optica.The frequency of anti-aquaporin-4 Ig g antibody in neuromyelitis optica and its spectrum disorders at a single tertiary referral center in malaysia.Optical Coherence Tomography Reveals Distinct Patterns of Retinal Damage in Neuromyelitis Optica and Multiple Sclerosis.Epithelial V-like antigen mediates efficacy of anti-alpha₄ integrin treatment in a mouse model of multiple sclerosisCD19 as a molecular target in CNS autoimmunity.Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).Plasmablasts as migratory IgG-producing cells in the pathogenesis of neuromyelitis opticaB lymphocytes in neuromyelitis opticaThe Correlation between Aquaporin-4 Antibody and the Visual Function of Patients with Demyelinating Optic Neuritis at Onset.The role of anti-aquaporin 4 antibody in the conversion of acute brainstem syndrome to neuromyelitis optica.Current options for the treatment of optic neuritis.Present and Future Therapies in Neuromyelitis Optica Spectrum DisordersRituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorderEpigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes.Evaluation of aquaporin-4 antibody assays.Treatment of Neuromyelitis Optica: Review and Recommendations.Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab.
P2860
Q24598109-8183772A-1042-4D38-B811-7384165F361BQ26768649-CA0F90B4-E094-4617-8831-1F51DD8BE66CQ26779910-F582E824-7C0F-4978-BCB2-644F44E2A586Q26796643-DB74075C-CFE5-4888-8D94-9A53F472FBA7Q26824579-3F804290-7274-455A-BD7D-C54BD13BE3EDQ27006941-B1B91775-BA8C-461D-8D81-83FF1100643CQ27016045-FEE7D946-EA8A-4F46-A9A0-D56519E57799Q28245749-4CDBE74C-261D-4742-8754-10C79B3874A9Q28647496-00D7048B-79F7-4894-85BA-21125ED04628Q28728565-525DFAA5-4172-4298-AA00-9A5D9557FA45Q30371412-286154CB-9BDC-49E6-9B07-6CFDB41E7430Q30577078-9CDE3763-D42E-4910-BFDF-EC0E7C7DC90BQ30610471-2337BD78-565E-4718-B092-8854F5764DD7Q30649660-7C32F459-EBDB-408E-B4C8-5130A6EC0FB5Q30676331-8493A26D-3B75-471E-A045-7C843AF7D5DEQ30699740-DDF83504-3BEC-4F53-B250-D264652FE488Q30759627-5204486B-296A-45A0-9177-5BCD7D53A4E7Q30785267-98D64BA2-B060-4A0D-8571-E81A30F97B73Q33678297-499CB725-BA46-4245-8C01-FB85BEC5D3EEQ33734731-6E9FFC8E-4BA0-437B-BF5A-177F739F5BE5Q33808279-4938D422-B11D-4A10-B162-4ADDF3DC44FCQ33812063-FABB6258-16B8-44B6-823F-7A8A1C0C6227Q34399291-878EE893-6227-4997-BD28-23964F7FD644Q34762744-DA0C2675-24BF-44C5-9F66-85E520E2CCDBQ34785270-9921D97B-551F-4F28-A54C-30B6F1EBBBC3Q34948175-1CEC3882-E392-49FE-8C9E-1E233ABF2506Q34976749-F1DEB7BA-821A-4A2D-9F39-1F9F59662B2FQ35052199-68E04E30-F99B-498A-8D39-C114C494A161Q35067939-FCDC6435-A4D0-444A-90B4-2F95AA03B58FQ35591039-F3EDA920-6189-4171-8589-0B3156F27B13Q35640735-C5BAC68E-9878-482D-8294-C89C05352269Q36171516-E353A7DF-A26F-45C7-B44F-78BD84DCF50AQ36173222-55C1FD7D-BA2C-4FC2-A8E9-8229D83A2214Q36484394-A82DD17E-A4EF-4251-A050-6DF6DDB929C2Q36490876-5E9FB808-2C6C-45BF-A460-25B766EBA8B4Q36648907-91767F99-1519-4798-ABD8-1451B5616AF5Q36753462-60CD5207-98E7-4D77-ACB8-BE6B14F7D52CQ37404328-D76543F6-D39E-48F9-BDEE-F4B6D8C20434Q37588037-9419840C-A825-4C10-BF0C-FF8EB646D5BAQ37684228-3FBEE778-C076-48A9-B1CD-DD3AA56E5783
P2860
Failure of natalizumab to prevent relapses in neuromyelitis optica.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Failure of natalizumab to prevent relapses in neuromyelitis optica.
@en
Failure of natalizumab to prevent relapses in neuromyelitis optica.
@nl
type
label
Failure of natalizumab to prevent relapses in neuromyelitis optica.
@en
Failure of natalizumab to prevent relapses in neuromyelitis optica.
@nl
prefLabel
Failure of natalizumab to prevent relapses in neuromyelitis optica.
@en
Failure of natalizumab to prevent relapses in neuromyelitis optica.
@nl
P2093
P1433
P1476
Failure of natalizumab to prevent relapses in neuromyelitis optica.
@en
P2093
Achim Berthele
Ingo Kleiter
Kerstin Hellwig
Neuromyelitis Optica Study Group
Orhan Aktas
Ralf A Linker
Tania Kümpfel
P304
P356
10.1001/ARCHNEUROL.2011.216
P577
2012-02-01T00:00:00Z